🚀 VC round data is live in beta, check it out!
NFL Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for NFL Biosciences and similar public comparables like Abera Bioscience, Genenta Science, Pharma Equity Group, Jupiter Neurosciences and more.
NFL Biosciences Overview
About NFL Biosciences
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
Founded
2009
HQ
Employees
4
Website
Sectors
Financials (LTM)
EV
$12M
NFL Biosciences Financials
NFL Biosciences reported last 12-month revenue of — and negative EBITDA of ($5M).
In the same LTM period, NFL Biosciences generated ($5M) in EBITDA losses and had net loss of ($4M).
Revenue (LTM)
NFL Biosciences P&L
In the most recent fiscal year, NFL Biosciences reported revenue of — and EBITDA of ($3M).
NFL Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Gross Profit | — | XXX | ($2M) | XXX | XXX | XXX |
| EBITDA | ($5M) | XXX | ($3M) | XXX | XXX | XXX |
| Net Profit | ($4M) | XXX | ($2M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
NFL Biosciences Stock Performance
NFL Biosciences has current market cap of $16M, and enterprise value of $12M.
Market Cap Evolution
NFL Biosciences' stock price is $1.25.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12M | $16M | -0.3% | XXX | XXX | XXX | $-0.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNFL Biosciences Valuation Multiples
NFL Biosciences trades at (2.7x) EV/EBITDA.
NFL Biosciences Financial Valuation Multiples
As of April 21, 2026, NFL Biosciences has market cap of $16M and EV of $12M.
Equity research analysts estimate NFL Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NFL Biosciences has a P/E ratio of (4.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16M | XXX | $16M | XXX | XXX | XXX |
| EV (current) | $12M | XXX | $12M | XXX | XXX | XXX |
| EV/EBITDA | (2.7x) | XXX | (3.9x) | XXX | XXX | XXX |
| EV/EBIT | (2.6x) | XXX | (3.7x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | (6.7x) | XXX | XXX | XXX |
| P/E | (4.1x) | XXX | (6.5x) | XXX | XXX | XXX |
| EV/FCF | (2.9x) | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NFL Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
NFL Biosciences Margins & Growth Rates
NFL Biosciences' revenue in the last fiscal year grew by —.
NFL Biosciences' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.
NFL Biosciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | (85%) | XXX | 46% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
NFL Biosciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| NFL Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Abera Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Genenta Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharma Equity Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Jupiter Neurosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Wellgistics Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NFL Biosciences M&A Activity
NFL Biosciences acquired XXX companies to date.
Last acquisition by NFL Biosciences was on XXXXXXXX, XXXXX. NFL Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by NFL Biosciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNFL Biosciences Investment Activity
NFL Biosciences invested in XXX companies to date.
NFL Biosciences made its latest investment on XXXXXXXX, XXXXX. NFL Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by NFL Biosciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NFL Biosciences
| When was NFL Biosciences founded? | NFL Biosciences was founded in 2009. |
| Where is NFL Biosciences headquartered? | NFL Biosciences is headquartered in France. |
| How many employees does NFL Biosciences have? | As of today, NFL Biosciences has over 4 employees. |
| Is NFL Biosciences publicly listed? | Yes, NFL Biosciences is a public company listed on Euronext Paris. |
| What is the stock symbol of NFL Biosciences? | NFL Biosciences trades under ALNFL ticker. |
| When did NFL Biosciences go public? | NFL Biosciences went public in 2021. |
| Who are competitors of NFL Biosciences? | NFL Biosciences main competitors are Abera Bioscience, Genenta Science, Pharma Equity Group, Jupiter Neurosciences. |
| What is the current market cap of NFL Biosciences? | NFL Biosciences' current market cap is $16M. |
| Is NFL Biosciences profitable? | No, NFL Biosciences is not profitable. |
| What is the current EBITDA of NFL Biosciences? | NFL Biosciences has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of NFL Biosciences? | Current EBITDA multiple of NFL Biosciences is (2.7x). |
| What is the current FCF of NFL Biosciences? | NFL Biosciences' last 12 months FCF is ($4M). |
| What is the current EV/FCF multiple of NFL Biosciences? | Current FCF multiple of NFL Biosciences is (2.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.